Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Is Soaring Today

By Brian Feroldi - Mar 6, 2020 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another day, another double-digit percentage move for the biotech's stock.

What happened

Shares of Inovio Pharmaceuticals (INO 9.25%), a highly volatile "coronavirus stock," surged as much as 36% in early trading on Friday. Shares were up about 25% as of 11:33 a.m. EST. 

So what

There doesn't appear to have been any company-specific news to justify the huge rally. However, President Trump did sign an $8.3 billion emergency bill to fund efforts to combat the coronavirus Friday morning.

Scientists working in lab

Image source: Getty Images.

Traders appear to be bidding up Inovio's stock based on the theory that some of that emergency funding will find its way into the company's coffers. 

Now what

Inovio has been in the news a lot recently. Earlier this week, it announced that it has accelerated the timeline for the development of its experimental SARS-CoV-2 vaccine. Human trials are expected to begin in the U.S., China, and South Korea in April, and if the vaccine is found to be effective, the company has committed to producing 1 million doses of it before the end of the year.

That update caused the share price to spike 70% in a single day

With the coronavirus making headlines daily, there's no telling where Inovio Pharmaceuticals' stock could head next. It's possible that the biotech could earn a financial windfall from its efforts to stem the spread of COVID-19, but it's also possible that one of its many competitors could beat it to the punch with a working vaccine. Given the amount of uncertainty involved, I'm content to watch these biotechnology companies duke it out from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.89 (9.25%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.